Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors

Trial Profile

Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B; Haemorrhage
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 12 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top